Best Oncology Companies in Ontario, Canada
The 75 best Oncology companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Fusion Pharmaceuticals.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Ontario
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Fusion Pharmaceuticals Developer of targeted alpha therapeutics for the treatment of cancers | $171M | 77 mo ago | 106 | — | Acquired | 294 patents Patents concentrated in health & consumer products | — |
| 2 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 77 mo ago | — | Xiaonan Wang Co-Founder & CTO | Series D | — | — |
| 3 | Trillium Therapeutics Developer of therapeutics for the treatment of cancer | $102M | 69 mo ago | 33 | — | Acquired | 180 patents Immune checkpoint therapies targeting CD47 with antibody and combination strategies | — |
| 4 | Notch Therapeutics Developer of stem-cell derived immune cell therapies | $100M | 25 mo ago | 90 | Shreya Shukla Founder | Series A | 18 patents Engineered T‑cell immunotherapies from stem cells and AI‑driven cellular outcome prediction | — |
| 5 | StageZero Life Sciences Developer of liquid biopsy test for the detection of cancer and multiple diseases | $59M | 46 mo ago | 40 | James Tripp CEO | Public | — | — |
| 6 | Aptose Biosciences Targeted small molecules for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes. | $52M | 28 mo ago | 31 | — | Acquired | 69 patents Patents concentrated in health & consumer products | — |
| 7 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 21 mo ago | 11 | — | Series A | 38 patents Engineered multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 8 | 3T Biosciences Developer of T-cell-based cancer immunotherapies to fight cancer | $40M | 45 mo ago | 33 | Leah Sibener Co-Founder | Series A | 27 patents High‑density EGFR/ErbB2‑targeted antibodies for cancer diagnostics and therapy | — |
| 9 | Northern Biologics Developing antibody therapeutics for cancer and fibrosis | $40M | 133 mo ago | 21 | — | Acqui-Hired | 2 patents Patents concentrated in health & consumer products | — |
| 10 | Helix BioPharma Developer of therapies for the treatment and prevention of cancer 35Product top 14%Moat top 28%Funding top 34%Patents top 38% All 11 signals ▾Producttop 14% Moattop 28% Fundingtop 34% Patentstop 38% Innovationtop 44% Techtop 47% Talentbottom 49% Growthbottom 47% Newsbottom 43% Globalbottom 43% Marketbottom 23% Product: 5 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 110 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $36M | 10 mo ago | 7 | Jacek Antas Ceo & Chairman Of The Executive Board | Public | 110 patents Engineered T‑cell immunotherapies and antibody‑urease conjugates for cancer treatment | — |
| 11 | Exact Imaging Developer of micro-ultrasound based imaging device 45Funding top 28%Moat top 32%Growth top 35%Patents top 46% All 9 signals ▾Fundingtop 28% Moattop 32% Growthtop 35% Patentstop 46% Talentbottom 49% Innovationbottom 47% Techbottom 44% Globalbottom 42% Marketbottom 39% Funding: Raised $29.9M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 4 mo ago | 32 | Randy Aucoin President & CEO | Series D | 45 patents High-resolution micro-ultrasound imaging with needle guidance and perfusion analysis. | — |
| 12 | Arius Research Speciality company involved in discovery and development of antibody therapeutics for various cancer | $22M | 243 mo ago | 31 | David S Young Founder | Acquired | — | — |
| 13 | POINT Biopharma Developer of radiopharmaceuticals to treat cancer | $20M | 70 mo ago | 129 | Joe Mccann CEO | Acquired | 17 patents Therapeutic radiopharmaceuticals for PSMA-targeted cancer imaging and treatment | — |
| 14 | RNA Diagnostics Developer of diagnostic assays for the detection of cancer | $14M | 57 mo ago | 11 | — | Series A | 30 patents RNA disruption assays for monitoring cancer therapy response and treatment efficacy | — |
| 15 | Profound Medical Developer of image guided prostate ablation system for cancer treatment 80Patents top 25%Funding top 31%Innovation top 33%Tech top 34% All 12 signals ▾Patentstop 25% Fundingtop 31% Innovationtop 33% Techtop 34% Moattop 35% Growthtop 36% Newstop 39% Markettop 40% Fin. healthtop 41% Globaltop 44% AItop 45% Partnerstop 45% Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $13M | 6 mo ago | 131 | — | Public | 171 patents Image-guided thermal therapy systems and advanced ultrasound probe hardware for medical interventions | — |
| 16 | Miikana Therapeutics Developer of small molecules to treat various cancer | $7M | 264 mo ago | — | Dinesh Patel Co-Founder & CEO | Series A | — | — |
| 17 | Pattern Pharma Developer of immunotherapies to treat cancers and infectious diseases | $7M | 14 mo ago | 5 | — | Series A | — | — |
| 18 | Medifocus Developer of microwave generated heat therapy for Breast cancer and BPH | $6M | 142 mo ago | 9 | — | Late Stage | — | — |
| 19 | Xillix Technologies Real-time fluorescence imaging system | $6M | 245 mo ago | 7 | — | Deadpooled | 17 patents Fluorescence and reflectance endoscopic imaging systems for medical diagnostics | — |
| 20 | Telo Genomics Developer of non-invasive prognostic and diagnostic applications that improve disease treatment 37Moat top 31%News top 38%Talent top 39%Partners top 40% All 11 signals ▾Moattop 31% Newstop 38% Talenttop 39% Partnerstop 40% Patentstop 43% Fundingtop 44% AItop 45% Growthtop 48% Innovationbottom 48% Globalbottom 33% Marketbottom 24% Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 3 mo ago | 6 | Sherif Louis CEO | Public | 9 patents Genomic diagnostic assays for detecting and monitoring smoldering multiple myeloma | — |
| 21 | Xlv Diagnostics Digital X-ray imaging system initially focused on mammography applications | $3M | 144 mo ago | 3 | Sorin Marcovici CEO & President | Deadpooled | — | — |
| 22 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 1 mo ago | — | John Bell Co-Founder | Seed | — | — |
| 23 | Mitomics Molecular diagnostics based on mitochnodrial genome | $2M | 152 mo ago | — | Christopher Mitton CEO | Acqui-Hired | 57 patents Mitochondrial DNA deletion/ fusion biomarkers for cancer and UV‑damage diagnostics | — |
| 24 | Proteocyte Provider of diagnostic test to predict risk of developing cancers | $2M | 13 mo ago | 5 | — | Series A | — | 2 launchs |
| 25 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 53 mo ago | 2 | — | Series A | — | — |
| 26 | Tenomix Developer of cancer screening device for pathologists | $1M | 27 mo ago | 7 | Mike Lavdas Founder & Chief Technology Officer | Seed | — | — |
| 27 | IntelliStem Developer of cell therapy medicine for cancer patient | $1M | 48 mo ago | — | Riam Shammaa Founder & CEO | Seed | — | — |
| 28 | Focal Healthcare Guidance system for prostate biopsy | $870K | 117 mo ago | — | Chicuong La Founder and CEO | Seed | 8 patents Mechanical interfaces and counterbalance systems for medical imaging patient positioning | 1 partnership |
| 29 | StokedBio Developer of therapeutics based on AI technology 45Talent top 28%AI top 45%Funding top 46%Market bottom 37% All 5 signals ▾Talenttop 28% AItop 45% Fundingtop 46% Marketbottom 37% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 45/100 | $366K | 1 mo ago | — | Chris Sinclair Co-Founder | Seed | — | — |
| 30 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 35 mo ago | — | Paul Slyke Co-Founder & CSO | Acqui-Hired | — | — |
Top 12 Oncology companies in Ontario
#1
Series D · Markham, Ontario · founded 2013 · 32 employees$29.9Mraised▾
Exact Imaging has developed a micro-ultrasound based imaging device. The ExactVu system operates at 29MHz waves for higher resolution and is used for imaging prostate cancer and biopsies. The product has an integrated disposable needle biopsy apparatus for visualization and targeting of suspicious small regions. in real-time
- Feb 2026Series D$10M
- Aug 2019Series C$244.4K
- Feb 2019Series C$7.6M
- Jan 2017Series C$16.1M
#2
Public · Toronto, Ontario · founded 2008 · 131 employees$12.9Mraised▾
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
- Dec 2025Post IPO$6.5M
- Jan 2024Post IPO—
- Jul 2020Post IPO$46M
- Mar 2018Post IPO$34.5M
#3
Public · Aurora, Ontario · founded 1995 · 7 employees$36.2Mraised▾
Developer of therapies for the treatment and prevention of cancer. The pipeline candidates include topical interferon - alpha2b, and LDOS47 for the treatment of small-cell lung cancer and pancreatic cancer. The company also has a patented technology platform DOS47 focused on achieving better debilitation of cancer cells.
- Aug 2025Post IPO$1.7M
- Jan 2025Post IPO$2.1M
- Mar 2024Post IPO$1.4M
- Nov 2022Post IPO$3.4M
#4
Public · Toronto, Ontario · founded 2011 · 6 employees$5.5Mraised▾
Developer of non-invasive prognostic and diagnostic applications that improve disease treatment. The company has a proprietary technology that uses a quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. It is developing Telo-MM application to provide e information to medical professionals in the treatment of Multiple Myeloma.
- Mar 2026Post IPO—
- Dec 2024Post IPO$1.8M
- May 2023Post IPO$2M
- Jul 2021Post IPO$1.7M
#5
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
#6
Seed · Hamilton, Ontario · founded 2024$365.5Kraised▾
Developer of therapeutics based on AI technology. It offers AI-based platform for molecular property prediction and molecular design for drug discovery for antibacterial, antifungal, antiviral, and cancer applications.
- May 2026Seed$365.5K
#7
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
- Sep 2024Series A$35M
- Apr 2023Seed$8M
#8
Series A · Toronto, Ontario · founded 2018 · 5 employees$6.9Mraised▾
Pattern Pharma is developing immunotherapies to treat cancers and infectious diseases. Its lead candidate, PAR-1 modulates the innate immune system (dendritic cells, macrophages, and NK cells). The candidate is PRR (Pattern Recognition Receptor) TLR-4 agonist and is being tested a stand-alone product and in combination therapy.
- Apr 2025Series A$798.5K
- Feb 2024Series A$275K
- May 2021Series A$4.1M
- May 2021Seed$1.6M
#9
Series A · Toronto, Ontario · founded 2018 · 90 employees$100.5Mraised▾
Developer of stem-cell-derived immune cell therapies. The proprietary Engineered Thymic Niche (ETN) platform enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) are fully defined, feeder-free, and serum-free cultures into mature T cells and other types of immune cells.
- May 2024Series A$15.5M
- Feb 2021Series A$85M
#10
Series A · Toronto, Ontario · founded 2011 · 5 employees$1.6Mraised▾
Provider of diagnostic test to predict risk of developing cancers. The company's flagship product Straticyte uses antibodies for detecting clinically validated biomarkers that have been associated with oral cancers on biopsies of lesions. It uses a proprietary algorithm to analyze the distribution of these biomarkers and classifies patients into high risk or low risk for the development of oral cancer.
- May 2025Series A$21.7K
- Nov 2024Series A$4.1M
- Dec 2023Seed$36.9K
- Jul 2023Seed$37.9K
#11
Acquired · Mississauga, Ontario · founded 1986 · 31 employees$51.5Mraised▾
Aptose Biosciences (formerly Lorus Therapeutics) is developing therapeutics to treat life-threatening cancers such as such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) based on a patient’s specific gene expression signature. It is also creating proprietary companion diagnostic tools to identify predisposed sensitivities to targeted therapies for use as a single-agent or combination regimens. Its lead product, APTO-253 is for the treatment of AML and MDS. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, it also has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. Its large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).
- Jan 2024Post IPO$9.7M
- Apr 2014Post IPO$28.2M
- Dec 2013Post IPO$7M
- May 2012Post IPO$6.6M
#12
Public · Richmond Hill, Ontario · founded 1997 · 40 employees$58.8Mraised▾
StaDeveloper of liquid biopsy test for the detection of cancer and multiple diseases. The company has developed blood-based biomarker tests for the early identification of colorectal cancer known as ColonSentry which uses proprietary Sentinel principle technology. Also, it develops Aristotle mRNA-based, multi-cancer panel for screening multiple cancers.
- Aug 2022Post IPO$177K
- Mar 2022Post IPO$1.5M
- Nov 2021Post IPO$3.3M
- Dec 2020Post IPO$198.3K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Ontario is moving
A read on the academic research around Oncology in Ontario — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 51 papers.
- Ontario Institute for Cancer Research37
- Children\'s Hospital of Eastern Ontario8
- Public Health Ontario5
- Cancer Care Ontario2
- Ontario Power Generation1
- Cancer research1→6
- Tumor microenvironment1→11
- Immunotherapy3
- Tumor microenvironment3
- Immune system3
- Metastasis2
- Chimeric antigen receptor1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.